Analysis of pancreatic adenocarcinoma tumor staging and resection according to previous body mass index and diabetes duration

Pancreatology

Volumn 7, Issue 2-3, 2007, Pages 187-193

  Souza, Jean J S ^a   Machado, Marcel C C ^a   Cunha, Jose Eduardo P M ^a   Jukemura, Jose ^a   Nery, Marcia ^a   Wajchenberg, Bernardo L ^a   Pereira, Maria Adelaide A ^a   Corrêa Giannella, Maria Lucia ^a   Giannella Neto, Daniel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes mellitus; Obesity; Overweight; Pancreatic adenocarcinoma

Indexed keywords

ADULT; ARTICLE; BODY MASS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; EVALUATION; FEMALE; HOSPITAL ADMISSION; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OBESITY; PANCREAS ADENOCARCINOMA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 34447644903     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000104244     Document Type: Article

References (41)

1. Wunsch Filho V, Moncau JE: Cancer mortality in Brazil 1980-1995: regional patterns and time trends. Rev Assoc Med Bras 2002;48:250-257.
2. Niederhuber JE, Brennan MF, Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671-1677.
3. Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
4. DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-1484.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-1638.
6. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE: Obesity, recreational physical activity, and risk of pancreatic cancer in a large US Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:459-466.
7. Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH: The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am J Epidemiol 2005;162:222-228.
8. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-2878.
9. Schwartz SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein AH: A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Dig Dis 1978;23:1107-1114.
10. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J: Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-107.
11. Gullo L, Pezzilli R, Morselli-Labate AM: Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Eng J Med 1994;331:81-84.
12. Chow W, Gridley G, Nyré O, Linet MS, Ekbom A, Fraumeni, Jr. JF, Adami H: Risk of Pancreatic Cancer Following Diabetes Melito: A Nationwide Cohort Study in Sweden. J Nat Cancer Inst 1995;87:930-931.
13. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995;273:1605-1609.
14. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A: Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552-2558.
15. Batty GD, Shipley MJ, Marmot M, Smith GD: Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004;15:873-881.
16. Kessler II: Cancer mortality among diabetics. J Natl Cancer Inst 1970;44:673-686.
17. Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ: Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-19.
18. Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y: Canadian Cancer Registries Epidemiology Research Group. Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 2001;94:140-147.
19. Berrington de Gonzalez A, Sweetland S, Spencer E: A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003;89:519-523.
20. Fisher WE, Boros LG, Schirmer WJ: Reversal of enhanced pancreatic cancer growth in diabetes by insulin. Surgery 1995;118:453-457.
21. Fisher WE, Boros LG, O'Dorisio TM, O'Dorisio MS, Schirmer WJ: GI hormonal changes in diabetes influence pancreatic cancer growth. J Surg Res 1995;58:754-758.
22. Fisher WE, Boros LG, Schirmer WJ: Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 1996;63:310-313.
23. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE: Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21:310-320.
24. Kazakoff K, Cardesa T, Liu J, Adrian TE, Bagchi D, Bagchi M, Birt DF, Pour PM: Effects of voluntary physical exercise on high-fat diet-promoted pancreatic carcinogenesis in the hamster model. Nutr Cancer 1996;26:265-279.
25. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270.
26. Physical status: the use and interpretation of anthropometry: Report of a WHO Expert Committee. World Health Org 1995;854:1-452.
27. National Cancer Institute: http://www.cancer.gov/cancertopics/pdq/ treatment/pancreatic/HealthProfessional/page3. Last modified: 03/06/2006. Accessed on September 12, 2006.
28. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP: Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001;121:640-645.
29. Holroyde CP, Skutches CL, Boden G, Reichard GA: Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 1984;44:5910-5913.
30. Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K: Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 1984;44:1718-1724.
31. Bennegard K, Lundgren F, Lundholm K: Mechanisms of insulin resistance in cancer associated malnutrition. Clin Physiol 1986;6:539-547.
32. Karmody AJ, Kyle J: The association between carcinoma of the pancreas and diabetes melito. Br J Surg 1969;56:362-364.
33. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HF, Larsson J: Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80:1047-1050.
34. 2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 1995;15:2585-2588.
35. Valerio A, Basso D, Brigato L, Ceolotto G, Baldo G, Tiengo A, Plebani M: Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Biochem Biophys Res Commun 1999;257:622-628.
36. Schmied BM, Ulrich AB, Matsuzaki H, Li C, Friess H, Bochler MW, Andron-Sandberg A, Adrian TE, Pour PM: Alteration of the Langerhans islets in pancreatic cancer patients. Int J Pancreatol 2000;28:187-197.
37. Basso D, Valerio A, Seraglia R, Mazza S, Piva MG, Greco E, Fogar P, Gallo N, Pedrazzoli S, Tiengo A, Plebani M: Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002;24:8-14.
38. Valerio A, Basso D, Fogar P, Falconi M, Greco E, Bassi C, Seraglia R, Abu-Hilal M, Navaglia F, Zambon CF, Gallo N, Falda A, Pedrazzoli S, Plebani M: Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides. Clin Chim Acta 2004;343:119-127.
39. Pfeffer F, Koczan D, Adam U, Benz S, von Dobschuetz E, Prall F, Nizze H, Thiesen HJ, Hopt UT, Lobler M: Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas 2004;29:284-290.
40. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Pedrazzoli S, Plebani M: Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta 2005;357:184-189.
41. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valério A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M: Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta 2006;372:120-128.